Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07024693 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 2 months later Sep 2026 → Dec 2027
See other at-risk trials from Design Therapeutics, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Dec 2027
    • Enrollment increased: 28 → 70 participants
    • Study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 15 words
  2. Start date changed from estimate of Jul 2025 to Jul 30, 2025
    • Site details revised at 1 of 2 sites
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Trial Details
NCT Number NCT07024693
Lead Sponsor Design Therapeutics, Inc.
Conditions
(from sponsor)		 Fuchs Endothelial Corneal Dystrophy, Fuchs
Related terms Fuchs' Endothelial Dystrophy
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov